Aurinia Pharmaceuticals Inc. - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Aurinia Pharmaceuticals Inc. on March 20, 2017. The filing serves to incorporate by reference a news release regarding a significant capital raising event. The registrant is a foreign private issuer filing under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide specific revenue, profit, cash flow, margin, or debt figures. The primary financial metric disclosed is the successful closing of a public offering of common shares totaling US$173.1 million. This amount includes the full exercise of the underwriters' option to purchase additional common shares.
Material Changes
The material change reported is the increase in equity capital resulting from the US$173.1 million public offering. No comparative financial data or prior period metrics are included in this specific filing text to quantify changes in operating performance.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, risk factors, or contingencies beyond the announcement of the capital raise. The document focuses solely on the execution of the offering and its incorporation into the Registrant's Registration Statement on Form F-10.
Investor Verification Checklist
- Verify the final share count and price per share resulting from the US$173.1 million offering.
- Review the full text of the incorporated news release (Exhibit 99.1) for details on the use of proceeds.
- Confirm the status of the underwriters' option exercise and any associated fees.
- Check the updated Registration Statement on Form F-10 (File No. 333-206994) for further disclosures.